First ever risk tool predicts readmission rates for patients after undergoing TAVR

April 27, 2018

SAN DIEGO, April 26, 2018 - A new study looked at the effectiveness of novel risk tool to predict 30-day readmission rates in patients undergoing transcatheter aortic valve replacement (TAVR). This first ever tool calculates a score to help clinicians and medical professionals predict risk of 30-day readmission for TAVR patients and can be easily incorporated in patient electronic medical records (EMR). The study was presented today at the Society for Cardiovascular Angiography and Interventions (SCAI) 2018 Scientific Sessions.

More than five million Americans are diagnosed with heart valve disease each year (AHA). TAVR is a procedure used for intermediate and higher open surgical-risk patients with severe narrowing of the aortic valve. In TAVR, a prosthetic valve is implanted percutaneously in the place of the diseased native valve. Patients who undergo TAVR are typically older with higher prohibitive risks and greater number of clinical comorbidities. Nearly 15-20 percent of patients who undergo TAVR - a less invasive procedure to replace the heart's aortic valve - are readmitted within 30 days. Readmissions are costly to patient outcomes and are also associated with more than $40 billion in hospital costs annually.

The study analyzed patients in the Nationwide Readmissions Database (NRD) who underwent TAVR from January 2013 to September 2015. Complex survey methods, hierarchical regression and the 'rms' library were implemented to create a prediction ruler to determine probability for 30-day readmission. The study's researchers performed an internal calibration with bootstrapping.

During the study period, a total of 39,305 patients underwent endovascular TAVR, and 6,380 (16.2 percent) were readmitted within 30 days. The final risk tool included the following variables: chronic kidney disease, end stage renal disease on dialysis, anemia, chronic lung disease, chronic liver disease, atrial fibrillation, length of stay >5 days, acute kidney injury and discharge disposition. The c-statistic of the model was 0.63. A score of 212 was associated with a more than 30 percent readmission rate.

"The creation of this tool and the results of the study are very assuring because it allows for better understanding how patients should be managed peri-TAVR. By recognizing patients at higher risk of readmission, we can guide post discharge care coordination and improve transitions of care to decrease readmission, improve quality of life, reduce healthcare costs and ultimately impact mortality rates," said lead author Sahil Khera, MD, Massachusetts General Hospital.

"Use of the simple risk tool will allow the entire care team to quantify readmission risk and enhance our ability to provide personalized transitional care to hopefully mitigate this risk," said co-author Sammy Elmariah, MD, also from the Massachusetts General Hospital.

The authors are looking to start using this tool and incorporating into EMRs in hospital systems across the country in the near future.

Session Details: "Late-Breaking Clinical Science II: Derivation of a Simple Risk Tool to Predict 30-day Readmission after Transcatheter Aortic Valve Replacement" [April 27, 2018, 11:00 a.m. - 12:00 p.m. PDT, Seaport DE]
-end-
About SCAI

The Society for Cardiovascular Angiography and Interventions is a 4,200-member professional organization representing invasive and interventional cardiologists in approximately 75 nations. SCAI's mission is to promote excellence in invasive/interventional cardiovascular medicine through physician education and representation, and advancement of quality standards to enhance patient care.

For more information about the SCAI 2018 Scientific Sessions, visit http://www.scai.org/SCAI2018/Default.aspx.

Society for Cardiovascular Angiography and Interventions

Related Acute Kidney Injury Articles from Brightsurf:

Model predicts acute kidney injury requiring dialysis in patients with COVID-19
In a recent study, a new algorithm achieved good performance for predicting which hospitalized patients will develop acute kidney injury requiring dialysis.

New algorithm predicts likelihood of acute kidney injury
In a recent study, a new algorithm outperformed the standard method for predicting which hospitalized patients will develop acute kidney injury.

Acute kidney injury among African Americans with sickle cell trait and disease
New research examines the risk of acute kidney injury in people with sickle cell trait or disease, as well as the effect of acute kidney injury on kidney function decline in these individuals.

Study reveals risk factors for acute kidney injury after brain hemorrhage
Patients who suffer an intracerebral hemorrhage (ICH) face an increased risk of acute kidney injury (AKI) during their hospitalization.

SphingoTec's kidney function biomarker penKid® accurately detects acute kidney injury in infants
penKidĀ® (Proenkephalin), a unique biomarker for the real-time assessment of kidney function.

Acute kidney disease in critically ill COVID-19 patients
A current study [1] is the first to evaluate and characterize the occurrence of COVID-19-associated acute kidney injury (AKI) in a larger number of critically ill patients.

Acute kidney injury and end stage kidney disease in severe COVID-19
Many COVID-19 patients experience hematuria, proteinuria and elevated serum creatinine concentration early in the course of the disease.

Researchers reveal target in acute kidney injury prevention
Physician-Scientists and other researchers at Rush University Medical Center, in collaboration with colleagues at other institutions, have revealed a new treatment target that may help change the outcome for patients at risk of AKI.

Protein levels in urine after acute kidney injury predict future loss of kidney function
High levels of protein in a patient's urine shortly after an episode of acute kidney injury is associated with increased risk of kidney disease progression, providing a valuable tool in predicting those at highest risk for future loss of kidney function.

Sphingotec's biomarker penKid® predicts septic acute kidney injury
Sphingotec reports study data demonstrating that its proprietary renal function biomarker penKidĀ® (Proenkephalin) predicts acute kidney injury (AKI), multi-organ failure and mortality in sepsis patients presenting to the emergency department (ED).

Read More: Acute Kidney Injury News and Acute Kidney Injury Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.